Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: a single institution experience.
Torrisi R, Garcia-Etienne CA, Losurdo A, Morenghi E, Di Tommaso L, Gatzemeier W, Sagona A, Fernandes B, Rossetti C, Eboli M, Rubino A, Barbieri E, Andreoli C, Orefice S, Gandini C, Rota S, Zuradelli M, Masci G, Santoro A, Tinterri C. Torrisi R, et al. Breast. 2013 Aug;22(4):419-24. doi: 10.1016/j.breast.2013.03.013. Epub 2013 May 3. Breast. 2013. PMID: 23643803
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
Torrisi R, Bagnardi V, Pruneri G, Ghisini R, Bottiglieri L, Magni E, Veronesi P, D'Alessandro C, Luini A, Dellapasqua S, Viale G, Goldhirsch A, Colleoni M. Torrisi R, et al. Br J Cancer. 2007 Sep 17;97(6):802-8. doi: 10.1038/sj.bjc.6603947. Epub 2007 Aug 21. Br J Cancer. 2007. PMID: 17712311 Free PMC article. Clinical Trial.
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale G, Goldhirsch A, Colleoni M. Torrisi R, et al. Cancer Chemother Pharmacol. 2008 Sep;62(4):667-72. doi: 10.1007/s00280-007-0652-z. Epub 2007 Dec 7. Cancer Chemother Pharmacol. 2008. PMID: 18064460 Clinical Trial.
Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Orlando L, et al. Among authors: torrisi r. Breast. 2008 Oct;17(5):506-11. doi: 10.1016/j.breast.2008.03.007. Epub 2008 May 5. Breast. 2008. PMID: 18456496 Free article.
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
Torrisi R, Montagna E, Scarano E, Dellapasqua S, Cancello G, Iorfida M, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Torrisi R, et al. Breast. 2011 Feb;20(1):34-8. doi: 10.1016/j.breast.2010.06.005. Epub 2010 Jul 16. Breast. 2011. PMID: 20638282 Free article.
Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.
Torrisi R, Cardillo A, Cancello G, Dellapasqua S, Balduzzi A, Ghisini R, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Torrisi R, et al. Clin Breast Cancer. 2010 Dec 1;10(6):483-8. doi: 10.3816/CBC.2010.n.064. Clin Breast Cancer. 2010. PMID: 21147693 Clinical Trial.
153 results